How Investors Are Reacting To Microsoft (MSFT) Securing Extended Exclusive AI Rights With OpenAI

Microsoft Corporation +3.12%

Microsoft Corporation

MSFT

370.17

+3.12%

  • Microsoft and OpenAI announced a restructured partnership, valuing Microsoft's stake at US$135 billion and designating the company as OpenAI's primary 'frontier model partner' through 2032, securing exclusive IP licenses for Microsoft's use of OpenAI's models and products until then.
  • This updated arrangement is accompanied by ongoing legal scrutiny regarding Microsoft's AI infrastructure deals, while also providing the company continued access to core AI assets that are central to its enterprise cloud and AI ecosystem.
  • We'll explore how this multi-year extension of exclusive AI access could reinforce Microsoft's competitive positioning within the high-growth enterprise AI and cloud markets.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Microsoft Investment Narrative Recap

To be a long-term Microsoft shareholder today, you typically need to believe in the company’s strength as a foundational provider of cloud and AI infrastructure globally, with durable demand from enterprises for advanced digital tools. The recent partnership restructuring with OpenAI reinforces Microsoft’s access to next-generation AI models, supporting its leading position in cloud and productivity, but does not materially alter the main short-term catalyst: continued robust Azure and AI-driven cloud revenue growth. The biggest risk remains heavy capital spending requirements, if AI or cloud adoption disappoints, returns could face pressure. Among recent announcements, Confluent’s newly expanded integration with Microsoft OneLake and Fabric directly illustrates how Microsoft’s platform is attracting partners that want to deliver seamless real-time analytics and AI capabilities to enterprise customers. This supports Azure’s position as an ecosystem for innovation and highlights the scale of workloads driving Azure’s growth, the exact area investors will be watching most closely as the next earnings report arrives. Yet, under the surface, investors should be mindful of how Microsoft’s massive investments in AI infrastructure could impact future profitability if growth trends shift...

Microsoft's outlook anticipates $425.0 billion in revenue and $158.4 billion in earnings by 2028. This scenario is based on analysts forecasting 14.7% annual revenue growth and a $56.6 billion increase in earnings from the current $101.8 billion.

Uncover how Microsoft's forecasts yield a $621.03 fair value, a 15% upside to its current price.

Exploring Other Perspectives

MSFT Community Fair Values as at Oct 2025
MSFT Community Fair Values as at Oct 2025

Simply Wall St Community members have submitted 128 fair value estimates for Microsoft ranging from US$360 to US$621 per share. With capital expenditure needs a key risk, the range of expectations offers critical context for your own outlook on long-term returns.

Explore 128 other fair value estimates on Microsoft - why the stock might be worth as much as 15% more than the current price!

Build Your Own Microsoft Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Microsoft research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Microsoft research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Microsoft's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

  • Find companies with promising cash flow potential yet trading below their fair value.
  • Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
  • AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.